

Contents

Part I Basic Principles

A Historical Perspective on the Use of Radionuclides for Therapy	3
Volkan Beylergil, Jorge A. Carrasquillo, Wolfgang A. Weber, and Steven M. Larson	
Therapeutic Radionuclides: Production, Physical Characteristics, and Applications	11
Suresh C. Srivastava and Leonard F. Mausner	
Rhenium-188 Generator-Based Radiopharmaceuticals for Therapy	51
F. F. (Russ) Knapp, J. Kropp, and K. Liepe	
Generator-Based Radiopharmaceuticals for PET Dosimetry Before, During, and After Endoradiotherapy	83
Frank Rösch and Richard P. Baum	
Cyclotron-Based Radiopharmaceuticals for Nuclear Medicine Therapy	95
Jacques Barbet, Mickaël Bourgeois, and Jean-François Chatal	
Peptides for Nuclear Medicine Therapy: Chemical Properties and Production	105
S. M. Okarvi and H. R. Maecke	
Antibodies for Nuclear Medicine Therapy	125
David M. Goldenberg and Robert M. Sharkey	
Selective High Affinity Ligands: A New Class of Targeting Agents for Cancer Imaging and Therapy	139
Rod Balhorn and Monique Cosman Balhorn	
Inorganic Radionuclides for Nuclear Medicine Therapy	151
Yun-Sang Lee and Jae Min Jeong	
Pharma Considerations for Timely Development of Therapeutic Radiopharmaceuticals	165
Adrian D. Nunn	
Economic and Industrial Considerations for Marketing of Therapeutic Radiopharmaceuticals	173
Richard Zimmermann	

Part II Clinical Applications: Brain and Nasopharyngeal Tumors

Radioimmunotherapy of Brain Tumors	187
Gabriele Pöpperl	
Radiopeptide Therapy of Brain Tumors	199
Flavio Forrer and Dominik Cordier	
Intracavitary Use of Radionuclides and Treatment of Meningiomas	207
Mirco Bartolomei and Giovanni Paganelli	
Radio-Tympano-Sinu-Orthesis as a Treatment Option in Chronic Otitis Media and Paranasal Mucositis	215
Ulf Lützen and Eberhard Henze	

Part III Clinical Applications: Thyroid Cancer

Sodium Iodide Symporter in Thyroid Carcinoma	225
June-Key Chung	
Gene Expression Analysis by DNA Microarray in Papillary and Follicular Differentiated Thyroid Cancer	233
Barbara Jarzab and Daria Handkiewicz-Junak	
Ablation Therapy with Radioiodine in Adults and Children with Differentiated Thyroid Cancer	245
Christoph Reiners, Markus Dietlein, Frederik Verburg, and Markus Luster	
Redifferentiation Therapy in Thyroid Cancer	259
Markus Luster, Daria Handkiewicz-Junak, and Johannes W. Smit	
Maximal Safe Dose Method of I-131 in the Management of Recurrent/Metastatic Differentiated Thyroid Carcinoma	269
Jong Jin Lee and June-Key Chung	
Therapeutic Strategy of Papillary Microcarcinoma of the Thyroid Gland: A Nuclear Medicine Perspective	275
Otmar Schober and Burkhard Riemann	
UICC Classifications 1997, 2002 and 2009: What is the Impact on Thyroid Cancer Mangement?	283
Otmar Schober and B. Riemann	
Radioiodine Remnant Ablation: A Critical Review	289
Chandra Sekhar Bal and Ajit Kumar Padhy	
Follow-up of Thyroid Cancer Patients and Treatment of Distant Metastases	301
Martin Schlumberger, Maryse Brassard, and Sophie Leboulleux	

Medullary Thyroid Carcinoma	315
Jean-François Chatal, Françoise Kraeber-Bodéré, David M. Goldenberg, and Jacques Barbet	
Treatment of Progressive Dedifferentiated and Medullary Thyroid Cancer with Radiolabeled Somatostatin Analogs	323
Rebecca A. Dumont, Jan Mueller-Brand, and Martin A. Walter	
 Part IV Clinical Applications: Benign Thyroid Diseases	
Radioiodine Therapy of Hyperthyroidism (Toxic Goiter, Hyperfunctioning Nodule) and Non-Toxic Goiter: Procedures and Guidelines.	335
Markus Dietlein and Matthias Schmidt	
Radioiodine Therapy of Hyperthyroidism in Graves' Disease	347
Wai Yin Wong and Anthony Goh	
 Part V Clinical Applications: Primary and Metastatic Liver Cancer	
Radioembolization: Concepts and Procedures.	361
Javier Arbizu, José I. Bilbao, Puy Garrastachu, Macarena Rodriguez-Fraile, Inés Domínguez-Prado, Mercedes Iñarrairaegui, and Bruno Sangro	
Radioembolization: Clinical Results Hepatocellular Carcinoma.	379
Ahsun Riaz, Laura M. Kulik, and Riad Salem	
Radioembolization (Yttrium-90 Microspheres) for Metastatic Hepatic Malignancies	385
Andrew S. Kennedy	
Rhenium-188 Lipiodol for the Treatment of Hepatocellular Carcinoma (HCC).	393
Ajit Kumar Padhy	
New Approaches: Combined Local and Multimodal Strategies in the Treatment of Complex Neuroendocrine Liver Metastases	405
Alexander Petrovitch, Merten Hommann, Dieter Hörsch, Patricia Grau, Sándor Kónya, Arnold Schneider, and Richard P. Baum	
 Part VI Clinical Applications: Bone and Joint Disease	
Radiolabelled Bisphosphonates for Bone Pain Palliation	423
Manfred Fischer, Willm Uwe Kampen and Valerie Lewington	
Radionuclide Therapy of Bone Metastases Using Rhenium-188 Hydroxyethylidene Diphosphate	433
Jan Bucerius, Holger Palmedo, and Hans-Jürgen Biersack	

Treatment of Osteoblastic Skeletal Metastases by the Alpha-Emitting Bone-Seeker Radium-223.	447
Øyvind S. Bruland and Roy H. Larsen	
Radionuclide Therapy of Inflammatory Joint Diseases (Radiation Synovectomy, Radiosynoviorthesis)	459
Gynter Mödder	
Radionuclide Therapy for Bleeding Joints in Hemophilia	495
Emerita Andres-Barrenechea, Mary Chua, and Sandra Navarra	
 Part VII Clinical Applications: Hematological Malignancies	
Non-Hodgkin Lymphoma: Radioimmunotherapy Using Iodine-131 Labeled Murine Anti-CD20 Antibodies (¹³¹I-Tositumomab and Tositumomab, “Bexxar”)	505
Heather A. Jacene and Richard L. Wahl	
Treatment of Lymphoma with ¹³¹I-Chimeric Monoclonal Antibodies	527
J. Harvey Turner	
Non-Hodgkin’s Lymphoma High Dose Therapy	535
Janet F. Eary	
Yttrium-90 Labelled Anti-CD20 Radioimmunotherapy with Stem Cells Support	543
Chiara M. Grana and Giovanni Paganelli	
Fractionated Radioimmunotherapy of Non-Hodgkin Lymphoma with 90-Y-Labeled Anti-CD22 Antibody, Epratuzumab Tetraxetan	551
Françoise Kraeber-Bodéré, Alain Faivre-Chauvet, Caroline Bodet-Milin, Amandine Pallardy, William A. Wegener, Jean-Francois Chatal, and David M. Goldenberg	
Targeted Alpha Particle Therapy of Peritoneal Carcinomas	557
Christof Seidl and Reingard Senekowitsch-Schmidtke	
 Part VIII Clinical Applications: Endocrine Tumors	
I-131 Meta Iodobenzylguanidine Therapy.	571
Val Lewington	
Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors Expressing Somatostatin Receptors	583
Richard P. Baum and Harshad R. Kulkarni	
 Part IX Clinical Applications: Radioimmunotherapy	
Radioimmunotherapy of Tumors: Pretargeting with Bispecific Antibodies.	607
Robert M. Sharkey and David M. Goldenberg	

Targeted Radionuclide Therapy of Prostate Cancer	617
Stanley J. Goldsmith, Scott T. Tagawa, Shankar Vallabhajosula, Anastasia Nikolopoulou, Irina Lipai, and Neil H. Bander	
Radioimmunotherapy of Neuroblastoma	629
Shakeel Modak, Kim Kramer, and Neeta Pandit-Taskar	
Radioimmunotherapy in Metastatic Colorectal Cancer	639
Johannes Meller, Torsten Liersch, Birgit Meller, Kia Homayounfar, and Carsten-Oliver Sahlmann	
Radioimmunotherapy of Renal Cancer	663
Chaitanya Divgi	
Myeloablative Radioimmunotherapy in Conditioning of Acute Leukemia, MDS, and Multiple Myeloma Prior to Hematological Stem Cell Transplantation	669
Inga Buchmann	
 Part X Clinical Applications: Intravascular/Intracavitary/Interstitial and Epidemal Radionuclide Therapy	
Endovascular Brachytherapy to Prevent Restenosis After Percutaneous Coronary Intervention	687
Jörg Kotzerke and Sigmund Silber	
Locoregional Radionuclide Therapy of Primary and Metastatic Cancers	703
Franklin C. Wong	
Radionuclide Therapy for Skin Malignancies	717
Arthur Eung-Hyuk Cho, Min-Geol Lee, and Jong Doo Lee	
Epidermal Radionuclide Therapy: Dermatological High-Dose-Rate Brachytherapy for the Treatment of Basal and Squamous Cell Carcinoma	725
Cesidio Cipriani and Antioco F. Sedda	
 Part XI Radiation Biology and Dosimetry	
Patient-Specific Dosimetry, Radiobiology, and the Previously-Treated Patient	737
George Sgouros and Robert F. Hobbs	
Nuclear Medicine Dose Assessment	747
Michael G. Stabin	
Monte Carlo Methods in Nuclear Medicine	759
Manuel Bardiès and Michael Lassmann	
Dosimetry for Peptide Receptor Radionuclide Therapy	769
Marta Cremonesi and Christiane Schuchardt	

Comparison Between β-Emitting Isotopes and α-Emitters Regarding Their Effects on Cancer Cells	781
Maurits W. Geerlings	
Hormesis by Low Dose Radiation Effects: Low-Dose Cancer Risk Modeling Must Recognize Up-Regulation of Protection.	789
Ludwig E. Feinendegen, Myron Pollycove, and Ronald D. Neumann	
Animal Models for Developing Radiopharmaceuticals for Therapy	807
Steve Mather, Theodosia Maina, and Marion de Jong	
Dosimetry in Accidental Radiation Exposure	817
Mee Jang, Alan C. Perkins, and Byung Il Kim	
Potential Impact of Radiation Biology in Radiation Protection in Nuclear Medicine and Corresponding Regulatory Issues.	835
Michel H. Bourguignon	
Radiation Protection of Staff and Public	843
Arndt Rimpler and Ilona Barth	
Effects of Music on the Psyche of Neuroendocrine Tumour Patients Undergoing Peptide Receptor Radionuclide Therapy	853
Remigius Orjiukwu, Margot Staudinger, Daniel Putzer, Dietmar Waitz, Michael Gabriel, and Irene J. Virgolini	
 Part XII Radiation Planning and Perspectives of Radionuclide Therapy	
The Use of Dosimetry in the Planning of Patient Therapy	867
Michael A. Stabin and Glenn D. Flux	
PET for Radiotherapy Planning.	879
Ursula Nestle	
Hypoxia Imaging for Radiation Therapy Planning	891
Heikki Minn, Jan Seppälä, and Tony Shepherd	
Chemotherapy Combined with Radionuclide Therapy	901
Phillip G. Claringbold and J. Harvey Turner	
Role of Surgery in a Multidisciplinary Approach	909
Eric H. Liu and Irvin Modlin	
PET for Measuring Therapy Response After Radionuclide Therapy	917
Thomas C. Kwee, Sandip Basu, Harshad R. Kulkarni, Richard P. Baum, and Abass Alavi	
Developing Probes for Molecular Imaging	931
Jan Grimm	
Index	941